Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments

Launched by JING LI · Aug 30, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating a new way to monitor ovarian cancer in women who have undergone surgery. Specifically, it looks at a test called ctDNA, which can help detect tiny amounts of cancer cells that might remain in the body after treatment. By tracking these cells, the researchers hope to find out if ctDNA can predict whether the cancer will come back after surgery.

To participate in this study, women aged 18 and older with advanced ovarian cancer (specifically, stages IIIC to IVA) may be eligible. Participants will need to agree to undergo a surgery known as primary debulking surgery (PDS) or interval debulking surgery (IDS). Throughout the trial, participants will be monitored closely to see how effectively the ctDNA testing works in predicting cancer recurrence. If you're interested in joining the study or want to learn more, it’s important to discuss it with your healthcare provider to see if it’s the right option for you.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. ≥ 18 years old.
• • 2. Patients diagnosed with stage IIIC-IVA ovarian cancer through pathological examination.
• • 3. The participant has read and fully understands the patient information, and has signed the informed consent form.
• • 4. The patient is willing to undergo primary debulking surgery (PDS) or interval debulking surgery（IDS）. -
• Exclusion Criteria:
• • 1. Other tumors have been detected within the last 5 years.
• • 2. Organ transplant recipients or those who previously had non-autologous (allogeneic) bone marrow or stem cell transplants.
• • 3. Patients was deemed unsuitable to participate in this study by other researchers.
• • 4. Patients who have previously received neoadjuvant chemotherapy or targeted therapy.